The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study

Diabetes Obes Metab. 2024 Nov;26(11):5466-5469. doi: 10.1111/dom.15862. Epub 2024 Aug 19.

Linong Ji¹, Leili Gao¹, Zhikai Feng², Guoliang Chen², Jing Fu², Erin Morgan³, Sanjay Bhanot³, Shan Gao², Hongyan Zhang², Zicai Liang², Li-Ming Gan^{2

4

5

6}

¹ Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
² Suzhou Ribo Life Science Co. Ltd, Suzhou, China.
³ Ionis Pharmaceuticals, Carlsbad, California, USA.
⁴ Ribocure Pharmaceuticals AB, Gothenburg, Sweden.
⁵ Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁶ Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

No abstract available

Keywords: clinical trial; glucagon; pharmacodynamics; phase I‐II study; type 2 diabetes.

Publication types